Navigation Links
Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
Date:10/10/2007

nfused over 10 minutes. After 15 minutes, a second 10 minute infusion of vernakalant 2 mg/kg or placebo was given if AF persisted or atrial flutter was present. The primary efficacy measure was the percentage of patients demonstrating conversion to SR for at least one minute within 90 minutes of dosing. Patients demonstrating conversion within 90 minutes were categorized as responders. Other efficacy measures included median time to conversion and the percentage of patients still in sinus rhythm at hour 24 and day 7.

In this subanalysis, a significantly higher percentage of patients with acute AF given vernakalant (61.8 percent) demonstrated conversion to SR within 90 minutes compared to patients given placebo (5.1 percent), P<.0001. Conversion from AF to SR with vernakalant was rapid and sustained. Among vernakalant responders, median conversion time was 11 minutes, and SR was maintained for 24 h in 97 percent and for 7 days in 93 percent. Seventy-eight percent of vernakalant responders required only one dose of the drug.

The most common adverse events (AEs) in patients given vernakalant were taste disturbance (32.4 percent), sneezing (16.7 percent), nausea (15.7 percent) and dizziness (11.8 percent). The incidence of serious AEs was similar in the vernakalant and placebo treatment groups for both the entire period and the first 24 hours (11.8 percent vs. 15.3 percent and 3.9 percent vs. 1.7 percent, respectively).

About Atrial Fibrillation

Atrial fibrillation (AF) is an interruption of the normal sinus rhythm (arrhythmia) of the heart in which the atria, the two uppermost chambers of the heart, beat irregularly and at an extremely rapid rate.(1) During AF, rapid and uncoordinated electrical discharges are generated by the heart's natural pacemaker (sinoatrial node) and other parts of the atria. This causes ineffective contractions of the atria and reduces the ability of the heart to pump blood through the body. Symptoms include dizziness, h
'/>"/>

SOURCE Astellas Pharma US, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Blood Gas Analysis: The Pros and Cons of Point-Of-Care Testing
3. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
4. Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Womens Health Initiative Data
5. New Analysis of WHI Data Shows Reduced Levels of Coronary Artery Calcification, a Predictor of Cardiovascular Events, in Women aged 50-59 taking Estrogen Therapy
6. Haemacure Announces Preliminary Findings of its Plasma Discard Analysis
7. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
8. Poniard Pharmaceuticals Announces Promising Data From Interim Safety Analysis of Phase 1 Combination Trials of Picoplatin in Colorectal and Prostate Cancers
9. ARRIVE Registry Analysis Identifies Predictors of Stent Thrombosis in Real-World Use of Drug-Eluting Stents
10. Cypher Sirolimus-Eluting Coronary Stent Had Similar Results to Bypass Surgery and Better Outcomes Than Bare Metal Stents in Subgroup Analysis of Diabetic Patients With Multivessel Coronary Disease
11. New Analysis of Data Shows Treatment With Abbotts Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohns Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... September 1, 2015 BerGenBio AS ... announces that it has appointed Hilde Furberg ... to its Board of Directors, effective immediately. ... experience in pharma and biotech and is currently Senior ... company. Previously her role was Vice President and General ...
(Date:9/1/2015)... September 1, 2015 Diabetes, ... 2015 market research report that charts the changing ... the added health concerns resulting from the metabolic ... factors: cardiovascular disease (CVD). Complete report ... spread across 270 pages, profiling 66 companies and ...
(Date:9/1/2015)... 1, 2015  Valeant Pharmaceuticals International, Inc. (NYSE: ... that its affiliate has entered into a collaboration ... an exclusive license to develop and commercialize brodalumab. ... monoclonal antibody in development for patients with moderate-to-severe ... Valeant will hold the exclusive rights to develop ...
Breaking Medicine Technology:BerGenBio Appoints Non-Executive Directors 2Diabetes, Metabolic Syndrome and Cardiovascular Disease Market 2015 Research Report 2Diabetes, Metabolic Syndrome and Cardiovascular Disease Market 2015 Research Report 3Diabetes, Metabolic Syndrome and Cardiovascular Disease Market 2015 Research Report 4Valeant And AstraZeneca To Partner On Brodalumab 2Valeant And AstraZeneca To Partner On Brodalumab 3Valeant And AstraZeneca To Partner On Brodalumab 4
... Md., April 26, 2012 /PRNewswire-Asia/ -- Chindex International, Inc. (NASDAQ: ... providing health care services in China through the operations ... care hospitals and affiliated ambulatory clinics, today announced that ... first quarter of 2012 ended March 31, 2012 on ...
... 2012 Medical sales recruitment specialists Advance ... new global medical device survey for 2012-2013 suggesting a ... climate. The report, which was published this ... a highly detailed analysis drawn from ICD research,s panel ...
Cached Medicine Technology:Chindex International, Inc. to Report First Quarter 2012 Financial Results 2Advance Recruitment Delighted With Positive Outlook for Medical Device Sales Industry 2
(Date:9/1/2015)... ... September 01, 2015 , ... Award-winning adult film ... about their experiences of female beauty, women’s emotions, fertility, female violence and sexual ... well as their relationships with other men, documenting how the power balance between ...
(Date:9/1/2015)... ... September 01, 2015 , ... Elizabeth Callahan, MD, founder ... the first in the area to offer RADIESSE® filler treatment for volume loss in ... prominence of tendons and veins in the hands, delivering smooth, natural-looking results that can ...
(Date:9/1/2015)... ... September 01, 2015 , ... Anthony J. Tantillo, Esq., Attorney from William ... third consecutive year in a row. Through nomination, research and strategic evaluation processes, ... in Niagara Falls, New York, Tantillo is a Buffalo State College graduate of 1998. ...
(Date:9/1/2015)... ... 01, 2015 , ... Routines… every family has them. Whether it’s a morning ... for parents, caregivers and children too. Here are three reasons why routines can be ... more fluid. When a routine is implemented into a child’s schedule, they are able ...
(Date:9/1/2015)... ... ... A new episode of “Voices In America”, hosted by famous actor and voice ... There are over 100 different types of arthritis. One of the most popular is ... to shed light on this important topic. , Anyone who is nearing their golden ...
Breaking Medicine News(10 mins):Health News:Female Porn Director Explains Male Insecurities about Women in a New Book 2Health News:SkinSmart Dermatology in Sarasota is Now Offering RADIESSE to Rejuvenate Hands 2Health News:SkinSmart Dermatology in Sarasota is Now Offering RADIESSE to Rejuvenate Hands 3Health News:Back into the Swing of Things: How Family Routines Benefit Children 2
... areas of the heart muscle become poorly supplied with blood - ... attacks. If blood vessels could be encouraged to grow to reinforce ... of life. In diabetes, this is a frequent complication, and can ... or take months to do so. // ,Altering ...
... forward in their attempt to starve cancer tumours by ... them nutrients. Four drugs that disrupt angiogenesis - blood ... time to be effective. It also provides the first ... in effectiveness depending on the stage of cancer targeted. ...
... at risk of developing osteoporosis. While women are more likely ... It is estimated that at the age of 50, a ... osteoporotic fracture during her remaining lifetime. Drugs, which are used ... first category comprises agents, which limit the rate of bone ...
... cause damage to arteries - but now a new study ... Scientist reports this week that the number of people admitted ... around 80,000 in 1990 to nearly double that two years ... team have found that taking in cocaine causes a reaction ...
... exposed to moderate to high levels of organic solvents double ... a study published in the September issue in Occupational and ... decorators are at highest risk. The only factor common to ... and low sperm activity was repeated exposure to organic solvents. ...
... which adds to the health risks of passive smoking. It ... 24 per cent of lung cancer cases. Where people are ... a smoker or work in a smoky environment - a ... ,Researchers at California State University, showed in their new ...
Cached Medicine News:Health News:Osteoporosis Drugs: right time to take-off 2
... use with the Moto Alpha unit, these new pads ... in which several successive runs may be sealed with ... to prevent a microplate from sticking to the block ... level of sealing performance, which means you can use ...
... Designed for use with the Moto Alpha unit, these ... cycle sequencing, in which several successive runs may be ... Alpha unit is engineered to prevent a microplate from ... pads provide an improved level of sealing performance, which ...
Microseal 'M' mats, seals 96-well plates, reusable, pkg of 10...
Omniseal TD mat. Reusable rubber mat for sealing PCR plates. 5 pk....
Medicine Products: